Indaptus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial
Indaptus Therapeutics Inc. has announced updates on their ongoing INDP-D101 clinical trial involving the Decoy20 combination with the PD-1 inhibitor, tislelizumab. The trial, which is in the clinical stage, aims to explore innovative treatments for cancer and viral infections. The company has completed the monotherapy portion of the trial and initiated a cohort of seven patients for the combination therapy. Among the first three evaluable patients in the combination therapy, one patient exhibited stable disease at the first assessment, while two experienced disease progression. Additionally, a patient in the monotherapy study displayed a partial response with a reduction in liver metastases, although the disease progressed at the next imaging. Indaptus plans to continue dosing additional patients and will present further results in the coming weeks.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012630), on September 04, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。